The DOI matches its Crossref record; 83 of the 83 references it cites were found in a registry or an index.
The Role of Tumor Necrosis Factor Alpha (TNF-α) in Autoimmune Disease and Current TNF-α Inhibitors in Therapeutics
Open accessAbstract
Tumor necrosis factor alpha (TNF-α) was initially recognized as a factor that causes the necrosis of tumors, but it has been recently identified to have additional important functions as a pathological component of autoimmune diseases. TNF-α binds to two different receptors, which initiate signal transduction pathways. These pathways lead to various cellular responses, including cell survival, differentiation, and proliferation. However, the inappropriate or excessive activation of TNF-α signaling is associated with chronic inflammation and can eventually lead to the development of pathological complications such as autoimmune diseases. Understanding of the TNF-α signaling mechanism has been expanded and applied for the treatment of immune diseases, which has resulted in the development of effective therapeutic tools, including TNF-α inhibitors. Currently, clinically approved TNF-α inhibitors have shown noticeable potency in a variety of autoimmune diseases, and novel TNF-α signaling inhibitors are being clinically evaluated. In this review, we briefly introduce the impact of TNF-α signaling on autoimmune diseases and its inhibitors, which are used as therapeutic agents against autoimmune diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED: The treatment of rheumatoid arthritis
Simon, L. S. (2004) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2004.04.005 · Cited by 19
RetractedA metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells
Black, R. A., Rauch, C. T., Kozlosky, C. J., Peschon, J. J., Slack, J. L., Wolfson, M. F., Castner, B. J., Stocking, K. L., Reddy, P., Srinivasan, S., et al. (1997) · Nature · doi:10.1038/385729a0 · Cited by 3,149
Boehncke, W.-H., & Schön, M. P. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61909-7 · Cited by 2,542
ROLE OF CYTOKINES IN RHEUMATOID ARTHRITIS
Feldmann, M., Brennan, F. M., & Maini, R. N. (1996) · Annual Review of Immunology · doi:10.1146/annurev.immunol.14.1.397 · Cited by 2,514
Cho, Y., Challa, S., Moquin, D., Genga, R., Ray, T. D., Guildford, M., & Chan, F. K.-M. (2009) · Cell · doi:10.1016/j.cell.2009.05.037 · Cited by 2,435 · cited 1×
“Complex IIc activates the mixed lineage kinase domain-like protein (MLKL) via RIPK3-mediated phosphorylation, which induces necroptosis and inflammation (Figure 1) [13,20].”
BackgroundCytokine Pathways and Joint Inflammation in Rheumatoid Arthritis
Choy, E. H. S., & Panayi, G. S. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103223441207 · Cited by 2,249
Pathogenesis and clinical features of psoriasis
Griffiths, C. E., & Barker, J. N. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61128-3 · Cited by 2,158
Necroptosis and its role in inflammation
Pasparakis, M., & Vandenabeele, P. (2015) · Nature · doi:10.1038/nature14191 · Cited by 2,148
Inflammatory bowel disease: cause and immunobiology
Baumgart, D. C., & Carding, S. R. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60750-8 · Cited by 2,147
TNF-mediated inflammatory disease
Bradley, Jr. (2008) · The Journal of Pathology · doi:10.1002/path.2287 · Cited by 2,094 · cited 1×
“It has been identified as a major regulator of inflammatory responses and is known to be involved in the pathogenesis of some inflammatory and autoimmune diseases [1].”
BackgroundPsoriasis Pathogenesis and Treatment
Rendon, A., & Schäkel, K. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061475 · Cited by 2,064
Inflammatory bowel disease: clinical aspects and established and evolving therapies
Baumgart, D. C., & Sandborn, W. J. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60751-x · Cited by 1,920
Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies
Guo, Q., Wang, Y., Xu, D., Nossent, J., Pavlos, N. J., & Xu, J. (2018) · Bone Research · doi:10.1038/s41413-018-0016-9 · Cited by 1,767
Tumor necrosis factor antagonist mechanisms of action: A comprehensive review
Tracey, D., Klareskog, L., Sasso, E. H., Salfeld, J. G., & Tak, P. P. (2008) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.10.001 · Cited by 1,628
Ritchlin, C. T., Colbert, R. A., & Gladman, D. D. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1505557 · Cited by 1,404
TNF biology, pathogenic mechanisms and emerging therapeutic strategies
Kalliolias, G. D., & Ivashkiv, L. B. (2016) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2015.169 · Cited by 1,387
Etanercept Therapy in Rheumatoid Arthritis: A Randomized, Controlled Trial
Moreland, L. W., Schiff, M. H., Baumgartner, S. W., Tindall, E. A., Fleischmann, R. M., Bulpitt, K. J., Weaver, A. L., Keystone, E. C., Furst, D. E., Mease, P. J., et al. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00004 · Cited by 1,379
Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-α
Moss, M. L., Jin, S.-L. C., Milla, M. E., Burkhart, W., Carter, H. L., Chen, W.-J., Clay, W. C., Didsbury, J. R., Hassler, D., Hoffman, C. R., et al. (1997) · Nature · doi:10.1038/385733a0 · Cited by 1,378
TNF-α Induces Two Distinct Caspase-8 Activation Pathways
Wang, L., Du, F., & Wang, X. (2008) · Cell · doi:10.1016/j.cell.2008.03.036 · Cited by 1,351
Grell, M., Douni, E., Wajant, H., Löhden, M., Clauss, M., Maxeiner, B., Georgopoulos, S., Lesslauer, W., Kollias, G., Pfizenmaier, K., et al. (1995) · Cell · doi:10.1016/0092-8674(95)90192-2 · Cited by 1,325
The Tumor Necrosis Factor Ligand and Receptor Families
Bazzoni, F., & Beutler, B. (1996) · New England Journal of Medicine · doi:10.1056/nejm199606273342607 · Cited by 1,225
Banner, D. W., D'Arcy, A., Janes, W., Gentz, R., Schoenfeld, H.-J., Broger, C., Loetscher, H., & Lesslauer, W. (1993) · Cell · doi:10.1016/0092-8674(93)90132-a · Cited by 1,104
Regulation of tumour necrosis factor signalling: live or let die
Brenner, D., Blaser, H., & Mak, T. W. (2015) · Nature Reviews Immunology · doi:10.1038/nri3834 · Cited by 998
Linear ubiquitination prevents inflammation and regulates immune signalling
Gerlach, B., Cordier, S. M., Schmukle, A. C., Emmerich, C. H., Rieser, E., Haas, T. L., Webb, A. I., Rickard, J. A., Anderton, H., Wong, W. W.-L., et al. (2011) · Nature · doi:10.1038/nature09816 · Cited by 940
Aggarwal, B. B., Gupta, S. C., & Kim, J. H. (2012) · Blood · doi:10.1182/blood-2011-04-325225 · Cited by 877
Transmembrane TNF- : structure, function and interaction with anti-TNF agents
Horiuchi, T., Mitoma, H., Harashima, S.-I., Tsukamoto, H., & Shimoda, T. (2010) · Rheumatology · doi:10.1093/rheumatology/keq031 · Cited by 864
Two tumour necrosis factor receptors: structure and function
Vandenabeele, P., Declercq, W., Beyaert, R., & Fiers, W. (1995) · Trends in Cell Biology · doi:10.1016/s0962-8924(00)89088-1 · Cited by 799
Haas, T. L., Emmerich, C. H., Gerlach, B., Schmukle, A. C., Cordier, S. M., Rieser, E., Feltham, R., Vince, J., Warnken, U., Wenger, T., et al. (2009) · Molecular Cell · doi:10.1016/j.molcel.2009.10.013 · Cited by 775
Sedger, L. M., & McDermott, M. F. (2014) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2014.07.016 · Cited by 771
Anti-TNF therapy: past, present and future
Monaco, C., Nanchahal, J., Taylor, P., & Feldmann, M. (2015) · International Immunology · doi:10.1093/intimm/dxu102 · Cited by 581
Keystone, E., Heijde, D. V. D., Mason, D., Landewé, R., Vollenhoven, R. V., Combe, B., Emery, P., Strand, V., Mease, P., Desai, C., et al. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23964 · Cited by 576
Koch, A. E., Harlow, L. A., Haines, G. K., Amento, E. P., Unemori, E. N., Wong, W. L., Pope, R. M., & Ferrara, N. (1994) · The Journal of Immunology · doi:10.4049/jimmunol.152.8.4149 · Cited by 575
Immunological pathogenesis of inflammatory bowel disease
Lee, S. H., Kwon, J. E., & Cho, M.-L. (2018) · Intestinal Research · doi:10.5217/ir.2018.16.1.26 · Cited by 575
Self-citationDeath receptor signal transducers: nodes of coordination in immune signaling networks
Wilson, N. S., Dixit, V., & Ashkenazi, A. (2009) · Nature Immunology · doi:10.1038/ni.1714 · Cited by 559
TNF and its receptors in the CNS: The essential, the desirable and the deleterious effects
Probert, L. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.06.038 · Cited by 495
Pathogenesis of psoriasis and development of treatment
Ogawa, E., Sato, Y., Minagawa, A., & Okuyama, R. (2018) · The Journal of Dermatology · doi:10.1111/1346-8138.14139 · Cited by 456
Role of TNF–TNF Receptor 2 Signal in Regulatory T Cells and Its Therapeutic Implications
Yang, S., Wang, J., Brand, D. D., & Zheng, S. G. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00784 · Cited by 410
Self-citationTumour necrosis factor signalling in health and disease
Holbrook, J., Lara-Reyna, S., Jarosz-Griffiths, H., & McDermott, M. F. (2019) · F1000Research · doi:10.12688/f1000research.17023.1 · Cited by 382
TNF Inhibition Rapidly Down-Regulates Multiple Proinflammatory Pathways in Psoriasis Plaques
Gottlieb, A. B., Chamian, F., Masud, S., Cardinale, I., Abello, M. V., Lowes, M. A., Chen, F., Magliocco, M., & Krueger, J. G. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.4.2721 · Cited by 372
Mechanism of Action of Anti-TNF Therapy in Inflammatory Bowel Disease
Levin, A. D., Wildenberg, M. E., & van den Brink, G. R. (2016) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjw053 · Cited by 336
Anti-TNF Therapy in Crohn’s Disease
Adegbola, S. O., Sahnan, K., Warusavitarne, J., Hart, A., & Tozer, P. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19082244 · Cited by 274
Pathogenesis of bone erosions in rheumatoid arthritis
Goldring, S. R., & Gravallese, E. M. (2000) · Current Opinion in Rheumatology · doi:10.1097/00002281-200005000-00006 · Cited by 249
Shealy, D. J., Cai, A., Staquet, K., Baker, A., Lacy, E. R., Johns, L., Vafa, O., Gunn, G., Tam, S., Sague, S., et al. (2010) · mAbs · doi:10.4161/mabs.12304 · Cited by 243
The Role of TNFα in Ulcerative Colitis
Sands, B. E., & Kaplan, G. G. (2007) · The Journal of Clinical Pharmacology · doi:10.1177/0091270007301623 · Cited by 214
Zhou, H., Jang, H., Fleischmann, R. M., Bouman‐Thio, E., Xu, Z., Marini, J. C., Pendley, C., Jiao, Q., Shankar, G., Marciniak, S. J., et al. (2007) · The Journal of Clinical Pharmacology · doi:10.1177/0091270006298188 · Cited by 191
Remicade® (infliximab): 20 years of contributions to science and medicine
Melsheimer, R., Geldhof, A. B., Apaolaza, I., & Schaible, T. (2019) · Biologics · doi:10.2147/btt.s207246 · Cited by 189
State of the art paper Tumor necrosis factor inhibitors – state of knowledge
Lis, K., Kuzawińska, O., & Bałkowiec-Iskra, E. (2014) · Archives of Medical Science · doi:10.5114/aoms.2014.47827 · Cited by 186
Biosimilars: Key regulatory considerations and similarity assessment tools
Kirchhoff, C. F., Wang, X. M., Conlon, H. D., Anderson, S., Ryan, A. M., & Bose, A. (2017) · Biotechnology and Bioengineering · doi:10.1002/bit.26438 · Cited by 179
Autoimmunity, Autoinflammation, and Infection in Uveitis
Forrester, J. V., Kuffova, L., & Dick, A. D. (2018) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2018.02.019 · Cited by 170
The role of TRADD in death receptor signaling
Pobezinskaya, E. L., & Liu, Z.-G. (2012) · Cell Cycle · doi:10.4161/cc.11.5.19300 · Cited by 169
McGovern, J. L., Nguyen, D. X., Notley, C. A., Mauri, C., Isenberg, D. A., & Ehrenstein, M. R. (2012) · Arthritis & Rheumatism · doi:10.1002/art.34565 · Cited by 162
Rau, R. (2002) · Annals of the Rheumatic Diseases · doi:10.1136/ard.61.suppl_2.ii70 · Cited by 159
Steeland, S., Libert, C., & Vandenbroucke, R. E. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19051442 · Cited by 156
Distinguishing rheumatoid arthritis from psoriatic arthritis
Merola, J. F., Espinoza, L. R., & Fleischmann, R. (2018) · RMD Open · doi:10.1136/rmdopen-2018-000656 · Cited by 155
Arijs, I., Hertogh, G. D., Machiels, K., Steen, K. V., Lemaire, K., Schraenen, A., Lommel, L. V., Quintens, R., Assche, G. V., Vermeire, S., et al. (2011) · The American Journal of Gastroenterology · doi:10.1038/ajg.2011.27 · Cited by 151
Dermatological adverse reactions during anti-TNF treatments: Focus on inflammatory bowel disease
Mocci, G., Marzo, M., Papa, A., Armuzzi, A., & Guidi, L. (2013) · Journal of Crohn s and Colitis · doi:10.1016/j.crohns.2013.01.009 · Cited by 146
Structural Biology of the TNFα Antagonists Used in the Treatment of Rheumatoid Arthritis
Lim, H., Lee, S. H., Lee, H., Lee, J., Son, J., Shin, W., & Heo, Y. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19030768 · Cited by 116
Self-citationPathogenesis of bone erosions in rheumatoid arthritis
Goldring, S. R. (2002) · Current Opinion in Rheumatology · doi:10.1097/00002281-200207000-00013 · Cited by 107
Adalimumab in the treatment of arthritis
Mease, P. J. (2007) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.2007.3.1.133 · Cited by 95
Rheumatoid arthritis: sequences
Scutellari, P. N., & Orzincolo, C. (1998) · European Journal of Radiology · doi:10.1016/s0720-048x(98)00040-0 · Cited by 95
Noninfectious uveitis in the Asia–Pacific region
Hsu, Y.-R., Huang, J. C., Tao, Y. K., Kaburaki, T., Lee, C. S., Lin, T.-C., Hsu, C., Chiou, S., & Hwang, D. (2018) · Eye · doi:10.1038/s41433-018-0223-z · Cited by 95
Clinical Use and Mechanisms of Infliximab Treatment on Inflammatory Bowel Disease: A Recent Update
Guo, Y., Lü, N., & Bai, A. (2013) · BioMed Research International · doi:10.1155/2013/581631 · Cited by 85
Quartuccio, L., Zabotti, A., Zotto, S. D., Zanier, L., Vita, S. D., & Valent, F. (2018) · Journal of Advanced Research · doi:10.1016/j.jare.2018.09.003 · Cited by 85
Jiang, Y., Yu, M., Xue-na, H., Han, L., YANG, K. Y., Ba, H., Zhang, Z., Yin, B., Yang, X., Li, Z., et al. (2017) · Cell Death and Differentiation · doi:10.1038/cdd.2016.162 · Cited by 84
Anti-TNF-α Antibody Therapies in Autoimmune Diseases
Chatzantoni, K., & Mouzaki, Α. (2006) · Current Topics in Medicinal Chemistry · doi:10.2174/156802606778194217 · Cited by 83
Kobayashi, T., Yokoyama, T., Ito, S., Kobayashi, D., Yamagata, A., Okada, M., Oofusa, K., Narita, I., Murasawa, A., Nakazono, K., et al. (2014) · Journal of Periodontology · doi:10.1902/jop.2014.140194 · Cited by 79
Mechanisms of action of infliximab in inflammatory bowel disease: an anti-inflammatory multitasker
Danese, S. (2008) · Digestive and Liver Disease · doi:10.1016/s1590-8658(08)60530-7 · Cited by 73
Saddala, M. S., & Hu, H. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-1965-5 · Cited by 71
Curtis, J. R., Xavier Mariette, A., Gaujoux-Viala, C., Blauvelt, A., Kvien, T. K., Sandborn, W. J., Winthrop, K. L., Longueville, M. D., Huybrechts, I., & Bykerk, V. P. (2019) · RMD Open · doi:10.1136/rmdopen-2019-000942 · Cited by 64
Azevedo, V. F., Galli, N., Kleinfelder, A. D. F., D’Ippolito, J. F., & Urbano, P. C. M. (2014) · Rheumatology International · doi:10.1007/s00296-014-3080-5 · Cited by 58
BIOLOGICS: TARGET-SPECIFIC TREATMENT OF SYSTEMIC AND CUTANEOUS AUTOIMMUNE DISEASES
Raychaudhuri, S., & Raychaudhuri, S. (2009) · Indian Journal of Dermatology · doi:10.4103/0019-5154.53175 · Cited by 56
Gilbert, R. M., Zhang, X., Sampson, R. D., Ehrenstein, M. R., Nguyen, D. X., Chaudhry, M., Mein, C. A., Mahmud, N., GALATOWICZ, G. E., Tomkins‐Netzer, O., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00907 · Cited by 51
Kotyla, P. J. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19061739 · Cited by 47
Psoriatic Synovitis: Singularity and Potential Clinical Implications
Celis, R., Cuervo, A. M., Ramírez, J., & Cañete, J. D. D. (2019) · Frontiers in Medicine · doi:10.3389/fmed.2019.00014 · Cited by 44
Ellingsen, T., Hornung, N., Moller, B. K., Poulsen, J. H., & Stengaard‐Pedersen, K. (2006) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.054056 · Cited by 42
Oldfield, V., & Plosker, G. L. (2009) · BioDrugs · doi:10.2165/00063030-200923020-00005 · Cited by 40
Sartori, N. S., Picon, P. D., Papke, A., Neyeloff, J. L., & Chakr, R. M. D. S. (2019) · PLoS ONE · doi:10.1371/journal.pone.0224963 · Cited by 40
Certolizumab pegol for the management of Crohn's disease in adults
Rivkin, A. M. (2009) · Clinical Therapeutics · doi:10.1016/j.clinthera.2009.06.015 · Cited by 38
Leal, I., Rodrigues, F. B., Sousa, D. C., Duarte, G. S., Romão, V. C., Marques‐Neves, C., Costa, J. N., & Fonseca, J. E. (2019) · Frontiers in Medicine · doi:10.3389/fmed.2019.00104 · Cited by 32
Tumor necrosis factor biologics beyond psoriasis in dermatology
Patel, R. M., Cafardi, J. M., Patel, N., Sami, N., & Cafardi, J. A. (2011) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2011.590798 · Cited by 21
Kwak, M. S., Lee, H. H., Cha, J. M., Shin, H. P., Jeon, J. W., & Yoon, J. Y. (2020) · Scientific Reports · doi:10.1038/s41598-020-67801-0 · Cited by 8
Self-citationBrambilla, A., & Simonini, G. (2016) · Technical report · doi:10.1016/b978-0-444-63596-9.00006-2 · Cited by 1
Komuro (2001) · doi:10.1002/1529-0131(200112)44:12
Research works printed but not linked: 14
- Morita, 2001, Association of tumor necrosis factor receptor type II polymorphism 196R with Systemic lupus erythematosus in the Japanese: Molecular and functional analysis, Arthritis Rheum., 44, 2819, 10.1002/1529-0131(200112)44:12<2819::AID-ART469>3.0.CO;2-2 · doi:10.1002/1529-0131(200112)44:12<2819::aid-art469>3.0.co;2-2
- Hasan, 2007, Angiotensin-Converting enzyme gene polymorphism in patients with psoriatic arthritis, Rheumatol. Int., 27, 1119, 10.1007/s00296-007-0349-y · doi:10.1007/s00296-007-0349-y
- Ringheanu, 2004, Effects of infliximab on apoptosis and reverse signaling of monocytes from healthy individuals and patients with Crohn’s disease, Inflamm. Bowel Dis., 10, 801, 10.1097/00054725-200411000-00015 · doi:10.1097/00054725-200411000-00015
- Rosenbaum, 2019, New observations and emerging ideas in diagnosis and management of non-infectious uveitis: A review, Semin. Arthritis Rheum., 49, 438, 10.1016/j.semarthrit.2019.06.004 · DOI
- Fearon, 2018, The pathogenic role of dendritic cells in non-infectious anterior uveitis, Exp. Eye Res., 173, 121, 10.1016/j.exer.2018.05.008 · doi:10.1016/j.exer.2018.05.008
- Reddy, S.P., Shah, V.V., Lin, E.J., and Wu, J.J. (2016). Therapy for Severe Psoriasis, Elsevier.
- Tan, 2007, Mechanisms of action of etanercept in psoriasis, J. Investig. Dermatol. Symp. Proc., 12, 38, 10.1038/sj.jidsymp.5650037 · doi:10.1038/sj.jidsymp.5650037
- Brambilla, A., and Simonini, G. (2016). Handbook of Systemic Autoimmune Diseases, Elsevier.
- LaMattina, 2017, Adalimumab for the treatment of uveitis, Expert Rev. Clin. Immunol., 13, 181, 10.1080/1744666X.2017.1288097 · doi:10.1080/1744666x.2017.1288097
- Rosa, 2016, An evidence-based review of certolizumab pegol in the treatment of active psoriatic arthritis: Place in therapy, Open Access Rheumatol., 8, 37
- Desai, 2012, Mixed Treatment Comparison of the Treatment Discontinuations of Biologic Disease-Modifying Antirheumatic Drugs in Adults with Rheumatoid Arthritis, Ann. Pharmacother., 46, 1491, 10.1345/aph.1R203 · DOI
- Shealy, 2007, Characterization of golimumab (CNTO 148), a novel fully human monoclonal antibody specific for human TNFα, Ann. Rheum. Dis., 66, 151
- Mazumdar, 2009, Golimumab, mAbs, 1, 422, 10.4161/mabs.1.5.9286 · doi:10.4161/mabs.1.5.9286
- Dahmus, 2020, Risk of Lymphoma Associated with Anti-TNF Therapy in Patients with Inflammatory Bowel Disease: Implications for Therapy, Clin. Exp. Gastroenter., 13, 339, 10.2147/CEG.S237646 · doi:10.2147/ceg.s237646
Cited by
Bifidobacterium Longum: Protection against Inflammatory Bowel Disease
Yao, S., Zhao, Z., Wang, W., & Liu, X. (2021) · Journal of Immunology Research · doi:10.1155/2021/8030297 · Cited by 255
Natarajan, N., Batts, S., & Stankovic, K. M. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12062347 · Cited by 254
Galbraith, M. D., Rachubinski, A. L., Smith, K. P., Araya, P., Waugh, K. A., Enriquez-Estrada, B., Worek, K., Granrath, R. E., Kinning, K. T., Paul Eduthan, N., et al. (2023) · Science Advances · doi:10.1126/sciadv.adg6218 · Cited by 88
New Insights into Adipokines in Gestational Diabetes Mellitus
Valencia-Ortega, J., González-Reynoso, R., Ramos-Martínez, E. G., Ferreira-Hermosillo, A., Peña-Cano, M. I., Morales-Ávila, E., & Saucedo, R. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23116279 · Cited by 39
Yu, W.-R., Jhang, J.-F., Jiang, Y.-H., & Kuo, H.-C. (2024) · Biomedicines · doi:10.3390/biomedicines12092051 · Cited by 39
Metadata
- Authors
- Jang, D.-I., Lee, A.-H., Shin, H.-Y., Song, H.-R., Park, J.-H., Kang, T.-B., Lee, S.-R., & Yang, S.-H.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2021-03-08
- Volume
- 22
- Issue
- 5
- Pages
- 2719
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W3134454558
- Cited by
- 1,694
- References
- 83
- FWCI
- 141.32
- Type
- journal article
- Language
- en
- Open access
- gold
- Funders
- Dongguk University Research Fund of 2019 (S-2019-G0001-00009)
- Cooperative Research Program for Agriculture Science & Technology Development of Rural Development Administration in Republic of Korea (Project No. PJ014297)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.